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Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary causative agent of 26 
enzootic pneumoniae (EP), one of the most economically important infectious disease 27 
for the swine industry worldwide. M. hyopneumoniae transmission occurs mainly by 28 
direct contact (nose­to­nose) between infected to susceptible pigs as well as from 29 
infected dams to their offspring (sow­to­piglet). Since disease severity has been 30 
correlated with M. hyopneumoniae prevalence at weaning in some studies, and gilts are 31 
considered the main bacterial shedders, an effective gilt acclimation program should 32 
help controlling M. hyopneumoniae in swine farms. The present review summarizes the 33 
different M. hyopneumoniae monitoring strategies of incoming gilts and recipient herd 34 
and proposes a farm classification according to their health statuses. The medication and 35 
vaccination programs against M. hyopneumoniae most used in replacement gilts are 36 
reviewed as well. Gilt replacement acclimation against M. hyopneumoniae in Europe 37 
and North America indicates that vaccination is the main strategy used, but there is a 38 
current trend in US to deliberately expose gilts to the pathogen. 39 
 40 
Keywords: Mycoplasma hyopneumoniae, gilt acclimation, adaptation strategies, 41 
Europe, North America  42 
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1. Introduction 43 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the causative agent of 44 
mycoplasmal pneumonia (MP), an important porcine respiratory disease. This infectious 45 
process is frequently complicated by other respiratory bacteria (such as Pasteurella 46 
multocida, Actinobacillus pleuropneumoniae and others) causing a more severe chronic 47 
and economically important disease known as enzootic pneumonia (EP). In addition to 48 
bacterial complication, viral pathogens like Porcine reproductive and respiratory 49 
syndrome virus, Porcine circovirus 2 and Swine influenza virus can aggravate the 50 
disease scenario; this viral­bacteria complex is clinically referred as porcine respiratory 51 
disease complex (PRDC) (Thacker and Minion, 2012). Despite all efforts implemented 52 
to reduce the economic impact caused by M. hyopneumoniae (vaccination and 53 
antimicrobial treatments together with improvement of management practices), EP and 54 
PRDC still cause great concern in the swine industry worldwide. 55 
EP mainly affects growing and finishing pigs and it is characterized by dry, non­56 
productive cough, reduction in growth rate, and increased feed conversion ratio. The 57 
severity of the disease is dependent on the presence of co­infections and environmental 58 
conditions (Maes et al., 1996) and on the virulence and number of M. hyopneumoniae 59 
strains involved (Vicca et al., 2003; Woolley et al., 2012; Michiels et al., 2017). M. 60 
hyopneumoniae is mostly transmitted by direct contact (nose­to­nose) between pigs, 61 
horizontally from infected to susceptible/naïve pigs (Morris et al., 1995) as well as from 62 
dam to their offspring (Sibila et al., 2008; Nathues et al., 2014; Pieters et al., 2014). 63 
Other putative indirect transmission routes are aerosol and fomites. Whereas the aerosol 64 
transmission has been experimentally proved (Fano et al., 2005; Otake et al., 2010), 65 
transmission by fomites has not been clearly demonstrated and it can be potentially 66 
prevented by basic biosecurity practices (Batista et al., 2004; Pitkin et al., 2011). 67 
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Different studies showed that disease severity in growing pigs is correlated with M. 68 
hyopneumoniae prevalence of piglet colonization at weaning (Fano et al., 2007; Sibila 69 
et al., 2008). However, other studies could not show this association (Vranckx et la, 70 
2012b). This prevalence can be influenced by different factors such as housing and 71 
management conditions of the production system as well as dam parity, piglet’s age at 72 
weaning and replacement rate (Nathues et al., 2013, 2014). Since newborn piglets are 73 
M. hyopneumoniae free, the most logical source of infection is the dam at the time of 74 
farrowing or during the lactation period (Sibila et al., 2007). Some authors suggested 75 
this transmission could be influenced by the dam’s parity (Calsamiglia and Pijoan, 76 
2000; Fano et al., 2006). Indeed, bacterial shedding of gilts or young sows seems to be 77 
higher than that of older parity sows (Boonsoongnern et al., 2012). Therefore, the first 78 
farrowing is considered a critical moment at which M. hyopneumoniae excretion should 79 
have ceased (Pieters and Fano, 2016). These latter data together with a low transmission 80 
rate (reproduction ratio [Rn] varies among 1.16­1.28 and 0.56­0.71 under experimental 81 
and field conditions, respectively) (Meyns et al., 2006; Villarreal et al., 2009; Roos et 82 
al., 2016) and the persistence of infection in pigs (up to 214 days post infection, dpi) 83 
(Pieters et al., 2009) imply the need of performing an effective gilt acclimation process. 84 
This effective acclimatization protocol would reduce M. hyopneumoniae shedding at 85 
first farrowing (Pieters and Fano, 2016) and, consequently, would decrease pre­weaning 86 
prevalence, subsequent spread of the pathogen to growing pigs, and putative respiratory 87 
problems in fattening animals (Fano et al., 2007; Sibila et al., 2008). Therefore, 88 
assuming that gilt population are crucial in the spread of the infection, the purpose of 89 
this review was to summarize different management practices, antimicrobial treatments 90 
and vaccination protocols in replacement gilts to control M. hyopneumoniae infections 91 




2. M. hyopneumoniae health status 94 
2.1. Monitoring and diagnosis 95 
One of the main risks for M. hyopneumoniae colonization in piglets at weaning is a 96 
high gilt replacement rate (Nathues et al., 2013). Therefore, the first step to perform an 97 
appropriate adaptation of future replacements to M. hyopneumoniae is monitoring the 98 
health status of the recipient breeding herd, as well as incoming gilts to detect potential 99 
disease/infection indicators. In case of M. hyopneumoniae infection suspicion, a 100 
definitive diagnosis should be performed.  101 
Monitoring of M. hyopneumoniae associated disease is sometimes challenging as 102 
the infection can take a clinical or subclinical course (Table 1). In clinical cases, the 103 
observation of signs (dry, non­productive coughing) and lung lesions (pulmonary 104 
craneo­ventral consolidation) are indicative, but not exclusive of M. hyopneumoniae. In 105 
subclinical infections, animals can display M. hyopneumoniae­like lung lesions without 106 
any evidence of coughing (Maes et al., 1996). Therefore, clinical diagnosis should be 107 
confirmed by additional laboratory tests (Table 1). 108 
The most commonly used herd monitoring method is M. hyopneumoniae antibody 109 
detection by ELISA. It provides evidence of exposure to M. hyopneumoniae without 110 
differentiating maternally derived antibodies, or antibodies elicited by infection, and/or 111 
vaccination (Bandrick et al., 2011; Thacker and Minion, 2012). Moreover, absence of 112 
antibodies (seronegative animals) may not be equivalent to a M. hyopneumoniae free 113 
status in early infection scenarios, suggesting that antibody and pathogen detection 114 
combined is the main goal for M. hyopneumoniae final diagnosis.  115 
Different laboratory techniques have been described to confirm the presence of M. 116 
hyopneumoniae (Table 1). The most useful technique to detect M. hyopneumoniae is 117 
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polymerase chain reaction (PCR), as it can be performed using different respiratory 118 
tract samples. Up to now, there is no consensus on which type of sample from the 119 
porcine respiratory tract is the most suitable to detect bacterial DNA in live pigs. To 120 
confirm M. hyopneumoniae free status of live animals or to determine the involvement 121 
of such pathogen in an outbreak, the desired sample should be collected from the lower 122 
respiratory tract (i.e. laryngeal or tracheo­bronchial swabs or tracheo­bronchial lavage 123 
fluids), where M. hyopneumoniae colonization of respiratory cilia occurs (Fablet et al., 124 
2010; Pieters et al., 2017). In dead animals, the sample of preference is lung tissue or 125 
bronchial swab.  126 
 127 
2.2. Recipient herd and incoming replacement classification regarding M. 128 
hyopneumoniae health status 129 
Once the M. hyopneumoniae health status of the recipient herds and the incoming 130 
gilts has been assessed, farms and incoming replacement could be classified into 131 
negative, provisional negative and positive according the following criteria 132 
(summarized in Table 2): 133 
Negative herds/replacement. Clinical signs and lung lesions associated with M. 134 
hyopneumoniae are not present and serology and detection of pathogen in lung by PCR 135 
are negative. This type of breeding and fattening farms is the less frequent one in the 136 
current swine production in Europe (Garza­Moreno et al., 2017). Nevertheless, M. 137 
hyopneumoniae negative farms are increasingly common among gilt producers, genetic 138 
companies, high health farms and in certain countries such as United States (US), where 139 
a trend for M. hyopneumoniae elimination is growing (Maria Pieters, personal 140 
communication).  141 
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Provisional negative herds/replacement. M. hyopneumoniae­like clinical signs and 142 
lung lesions are not observed but animals are seropositive and PCR negative. The 143 
presence of antibodies against M. hyopneumoniae provides evidence of exposure to the 144 
pathogen by prior infections and/or vaccination against it. This type of farms (PCR 145 
negative and seropositive) is frequently found in US since they are applying vaccination 146 
against M. hyopneumoniae (Maria Pieters, personal communication).  147 
Positive herds/replacement. These farms can be classified into subclinical infected 148 
or clinical affected. Subclinical infected farms can be differentiated in two different 149 
categories (I and II) according to the presence of ELISA antibodies against M. 150 
hyopneumoniae, the detection of the pathogen by PCR and the presence of lung lesions 151 
attributed to M. hyopneumoniae (Table 2). In category I, lung lesions associated to M. 152 
hyopneumoniae are not observed, the detection of antibodies depends on the disease 153 
phase (in early stages might not be detected) but the presence of the pathogen is 154 
confirmed. Animals from herds included in category II do not show clinical signs 155 
compatible with M. hyopneumoniae but have M. hyopneumoniae­like lung lesions, 156 
antibodies against the pathogen might be detected and the presence of M. 157 
hyopneumoniae is confirmed by PCR. Finally, in clinical affected farms, infected pigs 158 
also display signs and lung lesions associated to M. hyopneumoniae.  159 
 160 
3. Prevention and control 161 
3.1. Vaccination 162 
Vaccination against M. hyopneumoniae is the most commonly used strategy to 163 
control its associated diseases in worldwide swine production systems (Maes et al., 164 
2017). Most commercial vaccines against M. hyopneumoniae are inactivated whole­cell 165 
preparations or bacterins, combined with an adjuvant to induce a stronger immune 166 
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response (Haesebrouck et al., 2004). Administration route of these commercial vaccines 167 
is mainly intramuscular and the volume per dose can vary according to the vaccine used 168 
(Table 3). Besides bacterins, attenuated vaccines against M. hyopneumoniae are also 169 
available in Mexico and China (Feng et al., 2013).  170 
An alternative to commercial vaccines may be autogenous vaccines, based on 171 
isolated strains from the affected farm. These vaccines are not frequently used because 172 
of the difficulty to isolate M. hyopneumoniae strains and the apparent lack of vaccine 173 
safety and efficacy data. Although information is limited, a single study has compared 174 
the efficacy of immunization with homologous and heterologous strains against an 175 
experimental infection and no significant differences in protection were observed 176 
(Villarreal et al., 2012). Further investigation on new vaccines, as recombinant subunit 177 
or attenuated vaccines, is required to provide an effective and total protection against M. 178 
hyopneumoniae (Simionatto et al., 2013).  179 
Different vaccination schedules against M. hyopneumoniae have been implemented 180 
depending on the type of herd, production system, infection dynamics, and number of 181 
doses administered (Haesebrouck et al., 2004). Commercial vaccines are most 182 
frequently applied to piglets, prior to or after weaning (Alarcon et al., 2014). 183 
Additionally, previous studies have shown that the weaning process does not 184 
significantly affect vaccination efficacy (Arsenakis et al., 2016), although numerical 185 
differences in terms of performance among vaccinated and non­vaccinated groups were 186 
detected (Arsenakis et al., 2017). Piglet vaccination efficacy has been widely 187 
demonstrated by reduction of clinical signs and prevalence and severity of lung lesions, 188 
improvement of production parameters, decrease of treatment costs and, in some cases, 189 
lower mortality rates (Maes et al., 1996). Although vaccination against M. 190 
hyopneumoniae does not prevent infection (Pieters et al., 2010; Villarreal et al., 2011, 191 
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2012), it is able to reduce the number of microorganisms in the swine respiratory tract 192 
(Vranckx et al., 2012a; Woolley et al., 2012).  193 
Sow vaccination is less frequently applied, but gaining relevance every day (Bargen, 194 
2004). Nevertheless, a limited number of vaccines are currently licensed for the 195 
reproductive population (Table 3) and studies on their effect are scarce (Table 4). Dam 196 
vaccination sought to decrease the infectious pressure, lowering bacterial load and, 197 
consequently, transmission from sow to piglet (Vranckx et al., 2012b; Takeuti et al., 198 
2017), as well as conferring maternal immunity via colostrum (Bandrick et al., 2011). 199 
Indeed, some studies have shown that sow vaccination prior to farrowing is able to 200 
reduce dam­to­piglet transmission, the number of positive piglets from vaccinated sows 201 
(Ruiz et al., 2003), and the EP lung lesions of them at abattoir (Sibila et al., 2008).  202 
Gilt vaccination combined with optimal management strategies have also been 203 
suggested to stimulate the immune response against a controlled exposure to M. 204 
hyopneumoniae (Holst et al., 2015) or in endemically infected herds (Maes et al., 2008). 205 
Additionally, gilt vaccination is recommended to homogenize immunity of the 206 
replacement batch and avoid destabilization of recipient breeding herd (Bargen, 2004). 207 
This is especially important when replacement is external and originates from M. 208 
hyopneumoniae negative farms. In this situation, the introduction of negative 209 
replacement stock into positive farms may contribute to the development of 210 
subpopulations of non­infected pigs, increasing the risk of pathogen re­circulation and 211 
its persistence in the farm (Takeuti et al., 2017). 212 
The number of required vaccine doses, application timing and its benefits are not 213 
standardized for sows and gilts. Nowadays, single vaccination is more frequently used 214 
due to the ease of implementation in farm management practices. Nevertheless, 215 
multiple­dose vaccination against M. hyopneumoniae could elicit a booster effect of the 216 
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consecutive vaccine doses. The potential benefits of applying multiple vaccine doses in 217 
terms of reduction of shedding have not been yet investigated.  218 
 219 
3.2. Medication 220 
Since protection against M. hyopneumoniae infection and associated diseases 221 
conferred by commercial vaccines is not complete, antimicrobial treatments are 222 
frequently required in commercial swine farms to control disease outcome. 223 
 Mycoplasmas lack a cell wall, thus M. hyopneumoniae is resistant to β­lactam 224 
antibiotics. Nevertheless, several antibiotic classes are effective in reducing the 225 
incidence and severity of M. hyopneumoniae compatible lung lesions. Most commonly 226 
used antibiotics are macrolides, lincosamides, tetracycline, and fluoroquinolones, 227 
among others (Thacker and Minion, 2012). The route of administration can be 228 
parenteral or mixed in feed / water depending on antibiotic choice. 229 
Medication is currently used with different purposes. Parenteral medication is used 230 
to treat animals suffering from severe clinical signs, normally associated with EP and 231 
PRDC. Under field conditions medication is also commonly used to control M. 232 
hyopneumoniae infection by means of minimizing pathogen transmission. Medication 233 
of sows prior to farrowing could be utilized as an attempt to decrease the bacterial 234 
shedding to the offspring (Thacker and Minion, 2012; Holst et al., 2015). Nevertheless, 235 
it has been shown that antibacterial treatments do not eliminate the bacterium from the 236 
host, and shedding of M. hyopneumoniae can be detected in pigs after medication 237 
programs (Overesch and Kuhnert, 2017). Therefore, the use of antimicrobials should be 238 
limited and only justified in specific situations to avoid the development of 239 




3.3.  Acclimation scenarios in Europe and North America 242 
Different acclimation scenarios may be in place and should be managed according 243 
to health status of the recipient herds, as well as the replacement batch (Table 5). In 244 
addition, the different production systems, management practices, and acclimation 245 
strategies used could have an impact on the acclimation process performed. To 246 
understand these differences, available information about gilt acclimation strategies 247 
used in Europe and North America are detailed (Table 6).  248 
3.3.1. European scenario 249 
Information on gilt acclimation strategies for M. hyopneumoniae utilized in Europe 250 
is limited. Recently, Garza­Moreno et al. (2017) identified the current acclimation 251 
strategies used in this continent. In this investigation, information was collected by 321 252 
questionnaires voluntarily responded by 108 veterinarians from 18 countries. The 253 
questionnaires were focused on the assessment of M. hyopneumoniae herd status, 254 
replacement health status, acclimation strategies and methods utilized to determine its 255 
effect.  256 
This study showed that the most common replacement origin used in Europe was 257 
external and that most respondents knew M. hyopneumoniae health status of 258 
replacement on arrival, being in most of the cases seropositive. Nevertheless, only 28% 259 
of respondents verified this theoretical M. hyopneumoniae status, being ELISA, the 260 
most used technique (Garza­Moreno et al., 2017). 261 
Replacement acclimation against M. hyopneumoniae was performed in most 262 
participating European farms. Although most farms have isolation units where to 263 
specifically acclimate replacement stock, several farms did not have those facilities or 264 
respondents did not answer the question. Independently of these sites, the most used 265 
strategy to acclimate gilt was vaccination alone (58%), being the number of doses most 266 
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frequently administered at acclimation one and two doses. Other acclimation strategy 267 
used in Europe was the combination of vaccination together with natural exposure to 268 
potentially infected animals. However, an effective exposure to M. hyopneumoniae is 269 
difficult to reach into a natural infection scenario. Finally, among respondents who 270 
performed the acclimation on gilts, only around 25% of them verified the effect of the 271 
process, being the combination of ELISA and PCR tests the most used strategy.   272 
3.3.2. North American scenario 273 
The importance of proper gilt acclimation to the incoming breeding herd against M. 274 
hyopneumoniae is paramount and highly recognized in the North American swine 275 
industry. This importance can be evidenced in the assessment of M. hyopneumoniae 276 
health status of the replacement and the existence of facilities for acclimatization against 277 
herd pathogens (gilt development units; GDUs). GDUs are utilized to allow ample time 278 
to incoming gilt to gradually adopt the health status of the recipient herd. According to 279 
previous studies based on questionnaires collected in US (Fano and Payne, 2015) and 280 
Mexico (Centeno et al., 2016), these acclimation facilities are in most of the cases 281 
continuous flow (72% and 75%, respectively) allowing an effective gilt exposure to M. 282 
hyopneumoniae.  283 
Gilt vaccination in North American swine industry was also recognized as the most 284 
common practice used at acclimation (Fano and Payne, 2015; Centeno et al., 2016). 285 
Other methods as natural exposure to M. hyopneumoniae, alone or combined with 286 
vaccination, and contact with infected cull sows or/and piglets are also used to acclimate 287 
the gilts (Dalquist, 2014; Fano and Payne, 2015). Taking into account that pig­to­pig 288 
transmission of this bacterium has proven to be extremely slow (Meyns et al., 2004; 289 
Roos et al., 2016), the ratio of infected and naïve gilts as well as the time of exposure 290 
are crucial and should be considered to achieve an effective exposure. Recently, early 291 
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controlled exposure has been attempted to expose the gilts by administering (intra­292 
tracheally) lung tissue homogenate containing M. hyopneumoniae (Fano and Payne, 293 
2015; Centeno et al., 2016) to individual gilts or groups of them (via aerosol), since the 294 
success of exposure is higher when these controlled procedures are used (Sponheim A., 295 
2017). Finally, according to aforementioned studies, overall, the verification of gilt 296 
acclimation process is minimally performed in North American farms. 297 
 298 
4. Conclusion 299 
M. hyopneumoniae is a respiratory pathogen that causes important economic losses 300 
to the swine industry worldwide. A proper gilt acclimation against M. hyopneumoniae 301 
prior entrance into a recipient breeding farm could maintain the farm health stability and 302 
control respiratory disease caused by this pathogen. Gilt replacement acclimation 303 
procedures against M. hyopneumoniae in Europe and North America showed that 304 
vaccination is the main strategy used, but there is a current trend in the US to 305 
deliberately expose gilts to the pathogen. Further investigations are needed to identify 306 
the ideal gilt acclimation protocol taking into account that these strategies must be based 307 
on incoming and recipient herd health statuses and the characteristics of each farm. 308 
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